Core Insights - Sarepta Therapeutics announced a major restructuring involving a 36% workforce reduction, equating to 500 employees, aimed at saving approximately $400 million annually [1] - The FDA has mandated a black box warning for Sarepta's gene therapy drug, ELEVIDYS, due to risks of acute liver injury and acute liver failure [1] Legal Issues - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2][4] - The lawsuit alleges that Sarepta misled investors regarding the safety and efficacy of ELEVIDYS, claiming the company portrayed the drug as safe while withholding critical risk information [4][5] Safety Concerns - The lawsuit highlights that Sarepta failed to disclose significant safety risks associated with ELEVIDYS and inadequacies in clinical trial protocols [5] - A timeline of events indicates that Sarepta reported a patient death during a trial on March 18, 2025, followed by further disclosures of deaths and regulatory scrutiny [6][7][8] Regulatory Scrutiny - On July 25, 2025, the European Medicines Agency rejected ELEVIDYS due to questions about its effectiveness, leading to a further decline in Sarepta's stock price [9]

Core Points - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] - The lawsuit claims that Sarepta misled investors regarding the safety and efficacy of its gene therapy product, ELEVIDYS, for Duchenne muscular dystrophy [2] Group 1 - The lawsuit seeks to recover losses for Sarepta investors who were adversely affected by the alleged fraud [1] - The complaint alleges that ELEVIDYS posed significant safety risks, and that trial protocols failed to detect severe side effects [2] - It is claimed that the severity of adverse events would lead to a halt in recruitment and dosing in ELEVIDYS trials, attracting regulatory scrutiny [2] Group 2 - Investors who suffered losses during the relevant time frame have until August 25, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] - The firm Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders [4]

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2]. - Investors have until August 25, 2025, to request to be appointed to lead the case [2]. Group 2: Product and Allegations - Sarepta is focused on developing treatments for rare diseases, with Elevidys being its key product for Duchenne muscular dystrophy [3]. - Allegations state that Sarepta misrepresented the safety profile of Elevidys, claiming its benefits outweighed risks, while it is linked to fatal acute liver failure in some patients [3]. Group 3: Stock Performance and Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second patient death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third patient death related to Elevidys was reported on July 17, 2025, causing the stock to fall more than 40% on July 18, 2025 [5].

Core Viewpoint - Sarepta Therapeutics, Inc. has faced significant stock price decline following the reported deaths of patients in clinical trials for its gene therapy drug ELEVIDYS, leading to a securities class action lawsuit from investors [1][4][10]. Group 1: Company Developments - On July 18, 2025, Sarepta's shares closed down $7.89, a decrease of 36%, after the announcement of a third patient death related to its experimental gene therapy [1]. - The lawsuit focuses on Sarepta's disclosures regarding the safety and efficacy of ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - The FDA has placed Sarepta's investigational gene therapy clinical trials for limb-girdle muscular dystrophy on clinical hold due to the reported patient deaths [10]. Group 2: Legal Actions - A securities class action lawsuit has been filed, representing investors who acquired Sarepta securities between June 22, 2023, and June 24, 2025 [2]. - The lawsuit alleges that Sarepta made false and misleading statements about the safety of ELEVIDYS and failed to disclose critical information regarding patient deaths [5][6]. - Hagens Berman, the law firm investigating the case, is urging affected investors to report their losses and is looking for individuals with knowledge to assist in the investigation [3][11]. Group 3: Regulatory and Market Impact - Following the patient deaths, Sarepta halted recruitment and dosing in some ELEVIDYS clinical studies, which has attracted regulatory scrutiny [7][8]. - The severity of adverse events related to ELEVIDYS has raised concerns about the therapy's current and future approval prospects [8]. - H.C. Wainwright has reduced its price target for Sarepta to $0, reflecting the negative market sentiment following these developments [10].

Core Viewpoint - Sarepta Therapeutics, Inc. experienced a significant decline in share price following the report of a third patient death related to its experimental gene therapy drug, ELEVIDYS, leading to a 36% drop in stock value on July 18, 2025 [1]. Group 1: Company Developments - The company reported the death of a third patient treated with ELEVIDYS, resulting in shares closing down $7.89 [1]. - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2]. - The lawsuit focuses on Sarepta's disclosures regarding the safety and efficacy of ELEVIDYS, alleging that the company misled investors about the therapy's safety and potential for broader application [4]. Group 2: Legal and Regulatory Issues - The lawsuit claims that Sarepta made false statements and failed to disclose critical information, particularly regarding patient safety updates that began on March 18, 2025 [5]. - Following the initial death report, Sarepta halted recruitment and dosing in some clinical studies as requested by EU authorities [6]. - Subsequent deaths of patients treated with ELEVIDYS led to further regulatory scrutiny, including a safety communication from the FDA regarding acute liver failure risks [8]. Group 3: Market Reactions and Analyst Opinions - The financial press reported that following the lawsuit, H.C. Wainwright reduced its price target for Sarepta to $0, reflecting a loss of confidence in the company's future prospects [10]. - The investigation by Hagens Berman is focused on whether Sarepta misled investors about the safety and revenue potential of its gene therapies [11].

Core Viewpoint - The resignation of Vinay Prasad from the FDA after a brief tenure is seen as a significant event impacting the biopharmaceutical industry, particularly regarding gene therapies and vaccine approvals [1][5]. Group 1: Impact on Biopharmaceutical Companies - Following the news of Prasad's resignation, biopharmaceutical companies such as Replimmune surged nearly 70%, Sarepta increased by 14%, and Capricor rose by 21.2% in pre-market trading [2]. - Prasad's departure is perceived as a positive development for gene therapy and vaccine companies, as his tenure included critical decisions that limited patient options and raised concerns among investors [6]. Group 2: Regulatory Environment - During Prasad's short time at the FDA, the agency tightened the usage of COVID-19 vaccines and rejected new drug applications from Replimmune and Capricor, leading to significant declines in their stock prices [5]. - The FDA's recent unconventional regulatory actions regarding Sarepta Therapeutics' gene therapy Elevidys coincided with Prasad's resignation, indicating a potential shift in the agency's approach [5]. Group 3: Leadership and Public Perception - Prasad's resignation was reportedly under pressure from the White House due to public criticism, highlighting the challenges faced by FDA officials in maintaining credibility [5]. - Analysts suggest that appointing a more experienced official to replace Prasad could help restore market confidence in the FDA [6].

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Last week, Sarepta voluntarily and temporarily paused all U.S. shipments of Elevidys. Elevidys had received traditional approval in June 2024 for ambulatory Duchenne muscular dystrophy (DMD) patients aged four years and older with a confirmed DMD gene mutation. Previously, in June 2023, it secured accelerated, conditional approval for non-ambulatory DMD patients. As gene therapies continue to evolve as a promising frontier in medical treatment, regulatory scrutiny intensifies following safety concerns. Rece ...

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen ... More displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images) Sarepta's current distressed valuation makes it an attractive acquisition candidate for larger pharmaceutical companies seeking gene therapy capabilities. The company's expertise, intellectual property, and market-leading position in Duchenne treatments could command significant premiums in a take ...

NEW YORK, July 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submissio ...